Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment

dc.contributor.authorEigeliene Natalja
dc.contributor.authorSaarenheimo Jatta
dc.contributor.authorWichmann Viktor
dc.contributor.authorÖsterlund Pia
dc.contributor.authorJekunen Antti
dc.contributor.organizationfi=kliininen syöpätautioppi|en=Clinical Oncology|
dc.contributor.organization-code1.2.246.10.2458963.20.74725736230
dc.contributor.organization-code1.2.246.10.2458963.20.74978886054
dc.converis.publication-id67975580
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/67975580
dc.date.accessioned2025-08-27T22:33:42Z
dc.date.available2025-08-27T22:33:42Z
dc.description.abstract<p>In the era of personalized medicine, systemic treatment with chemotherapy in combination with targeted drugs, tailored according to RAS and BRAF status, has improved the survival of patients with metastatic colorectal cancer (mCRC), but curative resection of metastases provides the only chance of cure. Here, we present a 40-year-old male with rectal adenocarcinoma and multiple bilateral synchronous liver metastases who has achieved long-term remission with multimodal treatment without resection of all metastatic lesions. This case emphasizes the need of repeated multidisciplinary team assessments and change of treatment intent if extraordinary responses are seen. The initial therapy consisted of short-course radiotherapy and surgery of the primary tumor followed by oxaliplatin-based combination chemotherapy and panitumumab with disease control intent. A complete radiologic response in >20 liver metastases in segments II–VIII was obtained. A biopsy-verified relapse of 3 liver metastases occurred at 9 months of treatment pause. Subsequently, major liver resection of 8 lesions was performed (4 with adenocarcinoma and 4 with cicatrix showing the challenge of disappearing lesions), followed by 6 months of adjuvant-like therapy. No relapse in MRI, PET, or CT has been noted since liver resection 6 years ago. Comprehensive genomic profiling of the primary tumor and liver metastases had similar driver mutations representing a low level of gene alteration and low diversity, possibly explaining the exceptional treatment response.<br></p>
dc.format.pagerange1482
dc.identifier.jour-issn1662-6575
dc.identifier.olddbid202379
dc.identifier.oldhandle10024/185406
dc.identifier.urihttps://www.utupub.fi/handle/11111/46920
dc.identifier.urlhttps://www.karger.com/Article/FullText/519044
dc.identifier.urnURN:NBN:fi-fe2021120859692
dc.language.isoen
dc.okm.affiliatedauthorEigeliene, Natalja
dc.okm.affiliatedauthorJekunen, Antti
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherS. Karger AG
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.relation.doi10.1159/000519044
dc.relation.ispartofjournalCase Reports in Oncology
dc.relation.issue3
dc.relation.volume14
dc.source.identifierhttps://www.utupub.fi/handle/10024/185406
dc.titleMetastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
519044.pdf
Size:
476.15 KB
Format:
Adobe Portable Document Format
Description:
Publisher's PDF